Agility steers Imprimis to Phase III; Russia on the come up for clinical trials;

> CRO Agility Clinical has reached Phase III with sponsor Imprimis Pharmaceuticals ($IMMY), planning to test the safety and efficacy of Impracor, a treatment for osteoarthritic knee pain. News

> Thanks to ample resources and an uncomplicated regulatory environment, sponsors and CROs are flocking to Russia for clinical trials. Report

> Accenture is pouring millions of dollars into its R&D optimization technology, looking to compete with CROs. Article

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.